- Research article
- Open Access
iPSC-derived familial Alzheimer’s PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling
© The Author(s). 2018
- Received: 22 December 2017
- Accepted: 27 May 2018
- Published: 26 June 2018
Type 2 diabetes (T2D) is a recognized risk factor for the development of cognitive impairment (CI) and/or dementia, although the exact nature of the molecular pathology of T2D-associated CI remains obscure. One link between T2D and CI might involve decreased insulin signaling in brain and/or neurons in either animal or postmortem human brains as has been reported as a feature of Alzheimer’s disease (AD). Here we asked if neuronal insulin resistance is a cell autonomous phenomenon in a familial form of AD.
We have applied a newly developed protocol for deriving human basal forebrain cholinergic neurons (BFCN) from skin fibroblasts via induced pluripotent stem cell (iPSC) technology. We generated wildtype and familial AD mutant PSEN2N141I (presenilin 2) BFCNs and assessed if insulin signaling, insulin regulation of the major AD proteins Aβ and/or tau, and/or calcium fluxes is altered by the PSEN2N141I mutation.
We report herein that wildtype, PSEN2N141I and CRISPR/Cas9-corrected iPSC-derived BFCNs (and their precursors) show indistinguishable insulin signaling profiles as determined by the phosphorylation of canonical insulin signaling pathway molecules. Chronic insulin treatment of BFCNs of all genotypes led to a reduction in the Aβ42/40 ratio. Unexpectedly, we found a CRISPR/Cas9-correctable effect of PSEN2N141I on calcium flux, which could be prevented by chronic exposure of BFCNs to insulin.
Our studies indicate that the familial AD mutation PSEN2N141I does not induce neuronal insulin resistance in a cell autonomous fashion. The ability of insulin to correct calcium fluxes and to lower Aβ42/40 ratio suggests that insulin acts to oppose an AD-pathophysiology. Hence, our results are consistent with a potential physiological role for insulin as a mediator of resilience by counteracting specific metabolic and molecular features of AD.
Type 2 diabetes (T2D) is associated with an increased risk for dementia in the setting of hyperinsulinemia and peripheral insulin resistance [15, 30]. There is as yet no consensus on whether the most important cause of dementia in the setting of T2D is related to Alzheimer’s disease (AD), vascular cognitive impairment and dementia (VCID) or some novel form of cognitive impairment with a predilection for a shared pathogenesis with T2D [13, 22, 26]. Furthermore, there is no consensus on the nomenclature for how these phenomena are described. The only exception is stroke, where it is accepted that the brain develops insulin resistance as a result of stroke  but even here, the brain regions, cell types, and intracellular bases of post-stroke insulin resistance are not well-established . Other reports indicate that “brain insulin signaling” is diminished in patients with AD  and that insulin resistance and glucose hypo-metabolism seen in positron emission tomography (PET) brain scans predict cognitive outcome in humans . There is substantial interest in the repurposing of intranasal insulin as a means of improving brain insulin signaling and thereby the cognitive function of both healthy individuals  and AD patients .
Given the poorly defined molecular pathology of brain insulin resistance in AD, we began by examining various potential mechanisms for the development of human brain insulin resistance as a cell autonomous phenomenon in neurons. Recently, an intriguing potential clue emerged in a report that γ-secretase hypofunction can underlie insulin resistance in adipocytes . The most common mutations leading to familial Alzheimer’s disease (FAD) target the presenilin 1 (PSEN1) gene. Mutations in PSEN1 or its homologue PSEN2 are associated with hypofunction of the γ-secretase leading to an increase in the amyloid β (Aβ) 42:40 ratio and Αβ42. The main aim of this study then was to test whether neuronal insulin signaling is impaired in neurons from subjects carrying FAD genes that encode hypofunctional γ-secretase and whether insulin resistance contributes to the phenotype of AD.
We analyzed the effect of insulin signaling on Aβ speciation as well as a battery of other determinations (such as electrophysiological profiling, toxin sensitivity, etc) in iPSC-derived wildtype and FAD mutant PSEN2N141I neurons as well as their CRISPR/Cas9-corrected counterparts. We focused on a particular iPSC-derived neuronal subtype: the basal forebrain cholinergic neurons (BFCNs)  since these are believed to be one of the most vulnerable cells to early degeneration in AD. In many cases of early CI, the severity of the memory deficit appears to reflect the severity of the cholinergic deficiency [10, 11].
We observed that wildtype, PSEN2N141I and CRISPR/Cas9-corrected iPSC-derived BFCNs (and their precursors) showed indistinguishable insulin signaling profiles as determined by the apparent phosphorylation stoichiometry of the canonical insulin signaling pathway molecules. Chronic insulin treatment of BFCNs of all genotypes led to a reduction in the Aβ42/40 ratio. Unexpectedly, a previously reported CRISPR/Cas9-correctable effect of PSEN2N141I on calcium flux could be corrected by chronic exposure of BFCNs to physiologically stimulatory concentrations of insulin. Hence, the ability of insulin to correct calcium fluxes and to lower Aβ42/40 ratio suggests that insulin acts to oppose an AD-pathophysiology. Our results are consistent with a potential physiological role for insulin as a mediator of resilience by acting as an antagonist of specific metabolic and molecular features of AD.
iPSC-derived neuroprecursors of BFCNs display dose-dependent insulin signaling
Nomenclature and descriptions of iPSC lines used in this study
Normal (Corrected AD1)
Normal (Corrected AD2)
Western blot analyses indicated that insulin activated all the canonical targets at the concentration employed. For reference, the dose range utilized ranged from reported physiological levels  (10 ng/ml is approximately 1.72 nM) to hyperphysiological levels (1000 ng/ml). Note that our highest insulin dose, 172 nM, is comparable to Kahn’s standard dose of 100 nM that was used to study insulin signaling in iPSC-derived myotubes . We found that the effect of insulin was most robust on the phosphorylation of AKT (Fig. 1c and d), which is a key signaling node within the PI-3 K signaling pathway. Downstream of AKT, glycogen synthase kinase-3 β (GSK3β) and ribosomal protein S6 (pS6RP), which mediates the translational regulation through insulin were activated by insulin. Similarly, insulin phosphorylated mammalian target of rapamycin complex (pMTOR) in a dose responsive fashion . Importantly, insulin signaling was not reduced in neuroprecursor lines that carried the FAD-mutation. Thus, the insulin resistance effect of hypofunctional γ-secretase as reported in adipocytes  was not readily detectable in our iPSC-derived BFCNs harboring hypofunctional γ-secretase due to familial AD mutant PSEN2N141.
iPSC-derived BFCNs display dose-dependent insulin signaling
Insulin regulates Aβ production by BFCNs
Using the same experimental design, we tested the status of tau phosphorylation at Ser202/Thr205 (Additional file 1: Figures S2a, 2b), but failed to detect FAD mutation-related changes in tau phosphorylation.
Insulin promotes Ca2+ flux in iPSC-derived BFCNs
Alzheimer’s disease (AD) pathology is characterized by synaptic and neuronal degeneration together with accumulation of extracellular plaques composed of Aβ , as well as neurofibrillary tangles composed of hyper-phosphorylated tau . In terms of molecular pathogenesis, Aβ accumulation can be directly linked to some mutations leading to early onset FAD. However, in the vast majority of cases, i.e. in sporadic AD, the disease may begin with inflammation or lipid abnormalities and the plaques and tangles arise only later as the disease progresses . Multiple co-existent pathologies (vascular, synuclein, etc.) can further complicate the picture.
The causality dilemma is illustrated by evidence linking AD to insulin resistance. An early analysis of this relationship comes from the Rotterdam study where a significant association of T2D and dementia believed to be AD was reported . Additional epidemiological studies also reported similar links between T2D and dementia believed to be AD [1, 35], while others have observed that cognitively normal patients with T2D can show reduced cerebral glucose metabolism . The latter observation could potentially dovetail with the fact that most dementia phenotypes are preceded by cerebral glucose hypo-metabolism , but it is not at all clear that all T2D patients develop cognitive decline. These studies support the notion that AD and T2D may have additive or synergistic effects on brain glucose metabolism. This hypothesis however is limited in its ability to elucidate the exact nature and molecular underpinnings of the relevant neuropathology.
At least three studies using post-mortem brains have suggested that AD (or cognitive impairment) is associated with impaired insulin signaling. In one study, AD brains were reported to display changes in the distribution of the insulin receptor as well as a reduction in IRS-1 and IRS-2, supporting the notion that insulin signaling would be impaired in those brain regions . These observations complemented previous reports showing comparable reductions in mRNA levels within the insulin/IGF pathways . However, none of these data substitute for a functional assessment of insulin signaling. The more definitive test of impaired insulin signaling was performed by Talbot et al.. using postmortem brain slices from subjects that were cognitively impaired or with AD, demonstrating that insulin signaling was indeed impaired in neuronal populations . Taken together, these observations support the hypothesis that AD (and cognitive impairment) may be associated with disrupted insulin signaling in the brain.
Alternatively, some studies also suggest that AD is the causative or exacerbating factor for T2D [13, 35]. In this context, it is important to point out that brain insulin signaling controls systemic metabolism by regulating autonomic outflow from the brain to visceral organs such as liver and adipose tissue. The experimental induction of insulin resistance in a variety of brain regions and neuronal cell types has been found to impair metabolic control and increase the susceptibility to metabolic disease . Hence, a disruption of insulin signaling along with AD pathology in brain regions controlling metabolism, such as the hypothalamus, can increase the susceptibility to diabetes and underpin the association of AD with T2D. For example, our group recently showed that APP/PSEN1 amyloid-depositing mice exhibit reduced hypothalamic insulin signaling and are more susceptible to aging and over-nutrition induced prediabetes . It is possible that hypothalamic amyloidosis may contribute to this phenomenon and may further potentiate T2D due to reduced brain insulin signaling . A study by Calon et al summarizes this reciprocity by showing an enhanced sensitivity of triple transgenic amyloid-depositing mice to high fat diet and a reversal of memory deficits and decrease in soluble Aβ following insulin administration . These observations suggest that AD and T2D pathologies may be able to set up a self-perpetuating “vicious cycle” with one another.
At this point, the key questions are: how exactly does AD impair brain and neuronal insulin signaling and if neuronal insulin resistance is induced by AD pathology, is it a cell autonomous effect or secondary to altered in-vivo – including paracrine – regulation. As an example of paracrine regulation of insulin signaling, a recent study demonstrated that ApoE4 secreted from astrocytes binds to the insulin receptor and may reduce insulin signaling by trapping the insulin receptor in the endosome . FAD could similarly impair insulin signaling through altered paracrine signaling or indirect effects in the microenvironment resulting in available cytokines or metabolites. The fact that we did not find insulin signaling to be altered in neurons derived from several FAD forms supports this notion. Future studies that examine such paracrine signaling in co-culture models of astrocytes or glia cells with neurons will examine these possibilities.
In an earlier study, we generated basal cholinergic neurons from iPSC lines carrying the PSEN2N141I mutation, along with corresponding familial and isogenic controls . In the current study, we observed that both cholinergic neuroprecursors and BFCNs derived from iPSCs exhibit classic responses to insulin that are not affected by the presence of AD mutations.
We went on to test whether chronic exposure to insulin could affect the production of Aβ. Previous pulse-chase studies demonstrated that insulin reduces intracellular amyloid beta production by modulating βAPP trafficking . We observed a bimodal response where chronic insulin exposure resulted in the ostensibly beneficial reduction of the Aβ42/40 ratio. These results support the existence of additional mechanisms that synergize with insulin action in its potential regulation of amyloid production. These data correlate well with results from a human clinical trial using intranasal insulin administration in patients with mild cognitive impairment and mild to moderate AD. Unbiased exploratory analyses revealed that some subtle memory benefits resulted and that the memory changes were associated with changes in Aβ42 . These observations merit additional studies aimed at identifying factors that interact with insulin in modulating brain Aβ42, and to study the underpinnings generating the variabilities in Aβ42/40 that have been observed in our lab and in other labs using iPSC models of AD .
Finally, in our earlier study , we reported that electrophysiological parameters such as action potential frequency and amplitude were reduced in cells carrying the PSEN2 N141I mutation. Therefore, we decided to assess whether insulin could modulate calcium transients as a reflection of electrophysiological effects. We found that insulin promotes Ca2+ mediated-fluorescence in all lines tested, and that PSEN2 mutant lines show reduced responses compared to their isogenic control lines. These changes were normalized either when the mutation was corrected with CRISPR/Cas9 gene editing or when insulin was chronically administered, apparently leading to a physiological correction by promoting Ca2+ currents that enhanced synaptic transmission . These observations warrant future patch-clamp studies to best illustrate the nature of Ca2+ deficiencies in response to insulin. Furthermore, future studies would benefit by the inclusion of corresponding isogenic controls i.e., with engineered FAD mutations. These studies would help explain if the deficiency Ca2+ flux in the insulin-mediated response of the unrelated control line (which was lower than in all other lines), is a result of genetic background, and if FAD mutations would further dampen such responses.
In summary, wildtype, PSEN2N141I and CRISPR/Cas9-corrected iPSC-derived BFCNs (and their precursors) showed indistinguishable insulin signaling profiles as determined by the apparent phosphorylation stoichiometry of the canonical insulin signaling pathway molecules. Chronic insulin treatment of BFCNs of all genotypes led to a reduction in the Aβ42/40 ratio. Unexpectedly, a previously reported CRISPR/Cas9-correctable effect of PSEN2N141I on calcium flux could be corrected by chronic exposure of BFCNs to physiologically stimulatory concentrations of insulin. Taking this calcium flux-correction effect of insulin together with its Aβ42/40 ratio-lowering effect suggests that insulin action at each of these steps acts to oppose an AD-related phenomenon. Our results are consistent with a potential physiological role for insulin as a mediator of resilience by acting as an antagonist of specific metabolic and molecular features of AD.
Cell derivation and maintenance
All iPSC lines utilized in these studies were originally obtained from the NYSCF Repository and were propagated according to standard guidelines . The lines used were designated 28,945 (Control), 948 (AD1), 949 (fControl), and 950 (AD2). Additional clones with single point mutation corrections were generated from AD1 and AD2 using CRISPR technology as described . Briefly, the CRISPR/Cas9 system was engineered to target the PSEN2N141I locus by cloning a single guide RNA (sgRNA) into pSpCas9(BB)-2A-GFP (PX458). Subsequently, the cells were transfected with the vector and a complementary ssODN by electroporation to serve as a correctional template via homology-directed repair (HDR). All iPSC cell lines were expanded and maintained in serum-free mTeSR1 media (Stem Cell Technologies) in a feeder-free system using Cultrex (Trevigen). Media was supplemented with 10 μM ROCK inhibitor (Y27632, Stemgent) during cell passages.
The differentiation protocol has been described in detail in . Briefly, iPSC lines grown in mTeSR1 media were dissociated using Accutase (Sigma-Aldrich) and plated onto Cultrex (Trevigen) coated 6-well plates at a density of 400,000–1,000,000 cells per well. The cells were allowed to reach full confluency in mTeSR1 media before initiating the differentiation process. At the beginning of differentiation (day 0) and continuing to day 8, cells were maintained in Custom mTeSR1 media (Stem Cell Technologies) lacking pluripotency promoters (i.e., bFGF, TGF-Beta, Li-Cl, GABA and pipecolic acid). Starting on day 2, the media was supplemented with dual SMAD inhibitors (SB431542 10 μM plus LDN193189 250 nM, Selleck Chem) as well as the ventralizing agents SAG at 500 nM (R&D) and Purmorphamine at 2 μM (Stemgent). During this period of induction, the media were changed every other day. On day 9, the media were gradually switched to Brainphys media (Stemcell Technologies) supplemented with B27 (Life Technologies). At the end of this period, neural progenitors were generated and used in subsequent assays. Alternatively, neuroprogenitors were dissociated using Accutase and seeded in plates coated with branched polyethynilimine (0.1%, Sigma-Aldrich) and laminin (10 mg/mL, Life Technology) in Brainphys media + B27 supplement with nerve growth factor (NGF) (Alamone labs, 50 ng/mL) and brain derived neurotrophic factor (BDNF) (R&D, 50 ng/mL). For this protocol, the media were changed every 2 days until analysis.
Cells were cultured overnight using media supplemented with B27 without insulin (Thermofisher A1895601). After the overnight culture, insulin (Sigma Cat. 91077C) or vehicle was added to the media as indicated. Insulin was prepared fresh from frozen stocks every day before administration. For chronic studies, a daily dose of 1000 ng/ml of insulin or vehicle (PBS) was added.
Protein extraction and western blot analysis
Cells were washed with cold PBS and then lysed with cold RIPA buffer (Thermo Fisher Scientific) supplemented with a cocktail of phosphatase and protease inhibitors (Life Technologies). The cells were scraped from the plates and passed through a 23-gauge needle four times before centrifuging at 12000RPM for 20 min at 4 °C. After centrifugation, the supernatant was collected and protein concentration was measured using a BCA or a Bradford quantification assay (Thermo Fisher Scientific). Equal amounts of protein lysates were loaded into NuPage BisTris 4–12% gradient gels (Thermo Fisher Scientific) and then transferred to 0.45 μm PVDF membranes (Millipore). The membranes were blocked with TBS and Odyssey blocking buffer (LI-COR) for one hour at room temperature followed by an overnight incubation with primary antibodies at 4 °C. The following antibodies were used: phospho-mTOR (#2971), phospho-AKT (Thr308) (#4056), phospho-AKT (Ser473) (#9271), phospho-GSK-3β (Ser9) (#9323), phospho-S6-Ribosomal Protein (Ser235/236) (#2211) from Cell Signaling Technology; phospho-Tau (Ser202/Thr205) (MN1020) from Thermo Fisher Scientific; and β-Actin (sc-81,178) from Santa Cruz Biotechnology or Gapdh (g8795) from Sigma-Aldrich. After overnight incubation, membranes were washed 3X with TBS-Tween and stained for one hour with secondary antibodies- IR-Dye 800 Goat Anti-rabbit (LI-COR) and Dylight 680 Goat Anti-mouse (Thermo Fisher Scientific) – diluted at room temperature in 0.01% SDS TBS-Tween. Finally, the membranes were washed 4 times and scanned using Odyssey Classic (LI-COR). Image Studio Software (LI-COR) was used to quantify bands.
Calcium image staining and microfluorimetry in response to insulin
Cells were deprived of insulin for a period of 24 h as previously described, and then incubated with a 2.5 ng/μl solution of Fluo-4, AM in 0.01% Pluronic F-127 (Life Technologies) dissolved in cell media (1:1000) for 15 min at 37 °C. The cells were then washed twice with media and cultured with a Brainphys media lacking Phenol Red (Stem Cell Technologies) for an additional 15 min before recording fluorescence. For microfluorimetry, relative fluorescent units (RFUs) were obtained using a Flexstation 2 (Molecular Devices Corp.) that was set to record RFUs in a 96-well format for a period of 70 s in 0.6 s intervals using Softmax Pro software (Molecular Devices Corp.). The wavelengths used were - excitation at 485 nm, emission at 538 nm and cut-off at 530 nm. The RFUs were exported using Softmax Pro (Molecular Devices) and after recording the baseline fluorescence, the cells were treated with 1000 ng/ml insulin or vehicle for 25 s. Visual corroboration of Ca2+ activity in individual cells was obtained using coverslips that were transferred to a recording chamber mounted on an upright Olympus BX61 microscope and fluorescence was recorded at 2 Hz by a cooled CCD camera (Hamamatsu Orca R2). A baseline recording of transients was obtained for the first 180 s before insulin application (1000 ng/ml) via whole chamber perfusion at room temperature for a period of 420 s. Ca2+ transients were expressed in a form of ΔF(t)/F0, where F0 is a baseline fluorescence of a given region of interest and ΔF is a difference between current level of fluorescence F(t) and F0. Fluctuations of ΔF(t)/F0 that were less than 0.05 were considered as non-responses.
Enzyme-linked immunosorbent assay (ELISA)
Cells were plated in a 24-well plate with Brainphys media supplemented with B27 (minus insulin) and treated with 1000 ng/ml of insulin or equivalent volume of PBS daily for 3 days. On the third day, the culture media were collected 30 min after insulin administration and ELISAs were performed on these aspirates using β-Amyloid 40 and 42 kits (WAKO Chemicals) according to manufacturer’s instructions.
Western blot experiments, Aβ42/40 ELISAs and relative fluorescent units (RFUs) or ΔF(t)/F0 were analyzed for statistical significance using 2-Way ANOVA followed by Bonferroni post hoc tests. All statistical analysis was computed using PRISM 5. *, p < .05; **, p < .01; ***, p < .001.
CLM, SN, CB and SG were supported by the Mount Sinai Alzheimer’s Disease Research Center P50 AG05138 to Mary Sano. Scott Noggle by the Charles Evans Foundation, the Alzheimer′s Drug Discovery Foundation, and The NY Community Trust. Scott Noggle and Sam Gandy were jointly supported by the Cure Alzheimer’s Fund and by National Institutes of Health (NIH) grants R21AG042965 and U01AG046170 (to Eric Schadt, Bin Zhang, and Sam Gandy). Sam Gandy and Bin Zhang were also supported by R01AG057907. Sam Gandy was also supported by The Werber Family Foundation, the Scott and Jennifer Moskowitz Foundation, the Louis B. Mayer Foundation, the Georgianne and Dr. Reza Khatib Foundation, and the Sarah and Gideon Gartner Foundation. Rudolph Tanzi was supported by the Cure Alzheimer’s Fund. Maitane Ortiz-Virumbrales was a NYSCF-Druckenmiller Fellow and was supported by The Werber Family Foundation and U01AG046170.
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its Additional file 1].
CLM, MOV, LDG, VS and CB designed, performed, analyzed and interpreted in vitro insulin signaling studies. CLM, MOV, SN, CB, and SG wrote the manuscript. CLM and IK performed electro-physiological studies. CLM and MOV cloned CRISPR/Cas9 constructs. CLM and MOV generated CRISPR/Cas9-corrected lines. RET, MOV, SN, CB and SG contributed to data interpretation and manuscript editing. The authors appreciate the critical reading and discussion of this manuscript provided by Steven E. Arnold (Massachusetts General Hospital, Harvard Medical School). All authors read and approved the final manuscript.
Ethics approval and consent to participate
Prior to their participation, all donors of skin biopsies provided their written informed consent and study approval was obtained from Western Institutional Review Board.
Consent for publication
All authors declare their consent for publication of this manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661–6. https://doi.org/10.1001/archneur.61.5.66161/5/661.
- Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68:51–7. https://doi.org/10.1001/archneurol.2010.225.View ArticlePubMedGoogle Scholar
- Bedse G, Di Domenico F, Serviddio G, Cassano T. Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front Neurosci. 2015;9:204. https://doi.org/10.3389/fnins.2015.00204.View ArticlePubMedPubMed CentralGoogle Scholar
- Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29:1326–34. https://doi.org/10.1016/j.psyneuen.2004.04.003.View ArticlePubMedGoogle Scholar
- Bird TD, Lampe TH, Nemens EJ, Miner GW, Sumi SM, Schellenberg GD. Familial alzheimer’s disease in american descendants of the Volga germans: probable genetic founder effect. Ann Neurol. 1988;23:25–31. https://doi.org/10.1002/ana.410230106.View ArticlePubMedGoogle Scholar
- Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol. 2012;69:29. https://doi.org/10.1001/archneurol.2011.233.View ArticlePubMedGoogle Scholar
- Deng X-L, Liu Z, Wang C, Li Y, Cai Z. Insulin resistance in ischemic stroke. Metab Brain Dis. 2017;32:1323–34. https://doi.org/10.1007/s11011-017-0050-0.View ArticlePubMedGoogle Scholar
- Duan L, Bhattacharyya BJ, Belmadani A, Pan L, Miller RJ, Kessler JA. Stem cell derived basal forebrain cholinergic neurons from Alzheimer’s disease patients are more susceptible to cell death. Mol Neurodegener. 2014;9:3. https://doi.org/10.1186/1750-1326-9-3.View ArticlePubMedPubMed CentralGoogle Scholar
- Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of β-amyloid precursor protein trafficking by insulin reduces Intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001;21Google Scholar
- Haense C, Kalbe E, Herholz K, Hohmann C, Neumaier B, Krais R, Heiss W-D. Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging. 2012;33:867–77. https://doi.org/10.1016/j.neurobiolaging.2010.08.015.View ArticlePubMedGoogle Scholar
- Herholz K. Acetylcholine esterase activity in mild cognitive impairment and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2008;35:25–9. https://doi.org/10.1007/s00259-007-0699-4.View ArticleGoogle Scholar
- Iovino S, Burkart AM, Warren L, Patti ME, Kahn CR. Myotubes derived from human-induced pluripotent stem cells mirror in vivo insulin resistance. Proc Natl Acad Sci U S A. 2016;113:1889–94. https://doi.org/10.1073/pnas.1525665113.View ArticlePubMedPubMed CentralGoogle Scholar
- Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53:474–81.View ArticlePubMedGoogle Scholar
- Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2012;9:25–34. https://doi.org/10.1038/nrneurol.2012.236.View ArticlePubMedGoogle Scholar
- Laws SM, Gaskin S, Woodfield A, Srikanth V, Bruce D, Fraser PE, Porter T, Newsholme P, Wijesekara N, Burnham S, Doré V, Li Q-X, Maruff P, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Villemagne VL, Martins RN, Verdile G. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Sci Rep. 2017;7:9766. https://doi.org/10.1038/s41598-017-09577-4.View ArticlePubMedPubMed CentralGoogle Scholar
- Mandelkow EM, Mandelkow E. Tau in Alzheimer’s disease. Trends Cell Biol. 1998;8:425–7.View ArticlePubMedGoogle Scholar
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31:224–43. https://doi.org/10.1016/j.neurobiolaging.2008.04.002.View ArticlePubMedGoogle Scholar
- Ortiz-Virumbrales M, Moreno CL, Kruglikov I, Marazuela P, Sproul A, Jacob S, Zimmer M, Paull D, Zhang B, Schadt EE, Ehrlich ME, Tanzi RE, Arancio O, Noggle S, Gandy S. CRISPR/Cas9-correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2 N141I neurons. Acta Neuropathol Commun. 2017;5:77. https://doi.org/10.1186/s40478-017-0475-z.View ArticlePubMedPubMed CentralGoogle Scholar
- Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia. 1996;39:1392–7.View ArticlePubMedGoogle Scholar
- Paull D, Sevilla A, Zhou H, Hahn AK, Kim H, Napolitano C, Tsankov A, Shang L, Krumholz K, Jagadeesan P, Woodard CM, Sun B, Vilboux T, Zimmer M, Forero E, Moroziewicz DN, Martinez H, Malicdan MCV, Weiss KA, Vensand LB, Dusenberry CR, Polus H, Sy KTL, Kahler DJ, Gahl WA, Solomon SL, Chang S, Meissner A, Eggan K, Noggle SA. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods. 2015;12:885–92. https://doi.org/10.1038/nmeth.3507.View ArticlePubMedGoogle Scholar
- Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes. 2002;51:1256–62. https://doi.org/10.2337/DIABETES.51.4.1256.View ArticlePubMedGoogle Scholar
- Plum L, Belgardt BF, Brüning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. 2006;116:1761–6. https://doi.org/10.1172/JCI29063.View ArticlePubMedPubMed CentralGoogle Scholar
- Ruiz HH, Chi T, Lindtner C, Hsieh W, Ehrlich M, Gandy S, Buettner C. Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer’s disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. Alzheimers Dement. 2016; https://doi.org/10.1016/j.jalz.2016.01.008.
- Saber H, Himali JJ, Beiser AS, Shoamanesh A, Pikula A, Roubenoff R, Romero JR, Kase CS, Vasan RS, Seshadri S. Serum insulin-like growth factor 1 and the risk of ischemic stroke. Stroke. 2017;48:1760–5. https://doi.org/10.1161/STROKEAHA.116.016563. View ArticlePubMedPubMed CentralGoogle Scholar
- Shekhar S, Wang S, Mims PN, Gonzalez-Fernandez E, Zhang C, He X, Liu CY, Lv W, Wang Y, Huang J, Fan F. Impaired cerebral autoregulation-a common neurovascular pathway in diabetes may play a critical role in diabetes-related Alzheimer’s disease. Curr Res diabetes Obes J. 2017;2(3):555587.Google Scholar
- Sparling DP, Yu J, Kim K, Zhu C, Brachs S, Birkenfeld AL, Pajvani UB. Adipocyte-specific blockade of gamma-secretase, but not inhibition of notch activity, reduces adipose insulin sensitivity. Mol Metab. 2016;5:113–21. https://doi.org/10.1016/j.molmet.2015.11.006.View ArticlePubMedGoogle Scholar
- Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, Santa-Maria I, Zimmer M, Aubry S, Steele JW, Kahler DJ, Dranovsky A, Arancio O, Crary JF, Gandy S, Noggle SA. Characterization and molecular profiling of PSEN1 familial Alzheimer’s disease iPSC-derived neural progenitors. PLoS One. 2014;9:e84547. https://doi.org/10.1371/journal.pone.0084547.View ArticlePubMedPubMed CentralGoogle Scholar
- Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes? J Alzheimers Dis. 2005;7:63–80.View ArticlePubMedGoogle Scholar
- Stoeckel LE, Arvanitakis Z, Gandy S, Small D, Kahn CR, Pascual-Leone A, Pawlyk A, Sherwin R, Smith P. Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. F1000Research. 2016;5:353. https://doi.org/10.12688/f1000research.8300.2.PubMedPubMed CentralView ArticleGoogle Scholar
- Talboom JS, Velazquez R, Oddo S. The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease. npj Aging Mech Dis. 2015;1:15008. https://doi.org/10.1038/npjamd.2015.8.View ArticlePubMedPubMed CentralGoogle Scholar
- Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122:1316–38. https://doi.org/10.1172/JCI59903.View ArticlePubMedPubMed CentralGoogle Scholar
- Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, Lefrançois D, Virgili J, Planel E, Giguere Y, Marette A, Calon F. Insulin reverses the high-fat diet–induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes. 2014;63(12):4291–301.View ArticlePubMedGoogle Scholar
- Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian BT, Okonkwo OC, La Rue A, Hermann BP, Koscik RL, Jonaitis EM, Sager MA, Asthana S. Association of Insulin Resistance with Cerebral Glucose Uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol. 2015;72:1013–20. https://doi.org/10.1001/jamaneurol.2015.0613.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004;63:1181–6.View ArticlePubMedGoogle Scholar
- Zhao N, Liu C-C, Van Ingelgom AJ, Martens YA, Linares C, Knight JA, Painter MM, Sullivan PM, Bu G. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron. 2017;96:115–129.e5. https://doi.org/10.1016/j.neuron.2017.09.003.View ArticlePubMedPubMed CentralGoogle Scholar
- Zucker RS. Calcium- and activity-dependent synaptic plasticity. Curr Opin Neurobiol. 1999;9:305–13. https://doi.org/10.1016/S0959-4388(99)80045-2.View ArticlePubMedGoogle Scholar